Olanzapine for the Prevention of Postoperative Nausea and Vomiting

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amani Hassan Abdel-Wahab
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• ASA I and II patients

• undergoing ambulatory laparoscopic gynecologic surgery with general anesthesia

• patients have at least two of the four Apfel risk factors for PONV2

• Lack of history of psychiatric and psychotic illnesses.

Exclusion Criteria:

• ASA III and ≥ IV patients

• Psychological diseases

• History of chemotherapy

• have a pre-existing vestibular disorder or history of dizziness or preexisting nausea or vomiting in the 24 h before surgery, or were being treated with regular antiemetic therapy including systemic corticosteroids.